natgillin/translations-raw huggingface dataset:
- Immediately after you self-inject Firazyr or your caregiver injects you with Firazyr while you are experiencing a laryngeal attack (obstruction of the upper airway), you must seek medical care in a medical institution.
- Če si zdravilo Firazyr injicirate med laringealnim napadom (neprehodnost zgornjih dihal) ali vam ga injicira negovalec, se morate takoj po tem obrniti na zdravniško pomoč v zdravstveni ustanovi.
Dose (Injection Volume)
Odmerek (prostornina injiciranega zdravila)
- The recommended dose of Firazyr is one injection of 1 ml up to a maximum of 3 ml based on body weight injected subcutaneously (under the skin) as soon as you develop symptoms of an angioedema attack (for example increased skin swelling, particularly affecting the face and neck, increasing tummy pain).
Otroci in mladostniki, stari od 2 do 17 let - Priporočeni odmerek zdravila Firazyr je ena injekcija z odmerkom od 1 ml do največ 3 ml glede na telesno maso, injicirana subkutano (pod kožo) takoj, ko se pojavijo simptomi napada angioedema (npr. povečano otekanje kože, ki delno zajame obraz in vrat, okrepljene bolečine v trebuhu).
Patients experiencing a laryngeal attack should always seek medical advice and be observed in a medical institution also after having taken the injection at home.
Podatkov o dajanju nadaljnjih odmerkov pri istem napadu pri mladostnikih ali otrocih ni. Bolnik z laringealnim napadom se mora vedno obrniti na zdravnika in ga je treba opazovati v zdravstveni ustanovi, tudi če si je zdravilo injiciral že doma.
Firazyr is not recommended for use in children under 2 years of age or weighing less than 12 kg because it has not been studied in these patients.
manjšo od 12 kg, ker pri teh bolnikih študije niso bile izvedene.
Each ml of the solution contains 10 mg of icatibant.
En mililiter raztopine vsebuje 10 mg ikatibanta.
Median time to almost complete symptom relief (hours)
Čas do skoraj popolnega lajšanja simptomov (ure)
Firazyr is intended for subcutaneous administration preferably in the abdominal area.
Zdravilo Firazyr je namenjeno subkutani uporabi, najbolje v predelu trebuha.
Special populations
populaciji
If you get any side effects talk to your doctor.
Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom.
Refer to the patient information leaflet for instructions for use.
Glejte navodilo za uporabo glede navodil za uporabo zdravila.
- See section on instructions for use for the dose to inject.
- Za odmerek, ki ga je treba injicirati, glejte navodilo za uporabo zdravila.
12.0 All episodes (N = 56)
12,0 Vse epizode
1) Remove the caps on each end of the connector.
1) Odstranite pokrovčka z obeh strani vmesnika.
4) Remove the pre-filled syringe and connector from the graduated syringe.
4) Odstranite napolnjeno injekcijsko brizgo in vmesnik z brizge z oznakami za prostornino.
A total of 66 patients with attacks of HAE affecting the larynx were treated in these controlled Phase III clinical trials.
V teh nadzorovanih kliničnih preskušanjih 3. faze je bilo zdravljenih skupno 66 bolnikov s HAE, ki so prizadeli grlo.
• Open the tray by peeling back the seal.
• Odprite podstavek, tako da tesnilo povlečete nazaj.
3) Preparing the injection site
Priprava mesta injiciranja
51 kg to 65 kg
Od 51 kg do 65 kg
Firazyr 30 mg solution for injection in pre-filled syringe Icatibant
Firazyr 30 mg raztopina za injiciranje v napolnjeni injekcijski brizgi ikatibant
No dose adjustment is required in patients with renal impairment.
Pri bolnikih z okvaro ledvic prilagoditev odmerka ni potrebna.
If you are taking a medicine known as an Angiotensin Converting Enzyme (ACE) inhibitor (for example: captopril, enalapril, ramipril, quinapril, lisinopril) which is used to lower your blood pressure or for any other reason, you should inform your doctor before receiving Firazyr.
Če jemljete zdravilo, znano kot zaviralec angiotenzin konvertaze (zaviralec ACE) (na primer: kaptopril, enalapril, ramipril,
Firazyr 30 mg solution for injection in pre-filled syringe
Firazyr 30 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Rash Erythema Pruritus
izpuščaj eritem pruritus urtikarija
Remove the needle cap from the blister.
• Iz pretisnega omota odstranite pokrovček za iglo.
The active substance is icatibant.
Zdravila učinkovina je ikatibant.
• Remove the pre-filled syringe from the tray.
• Napolnjeno injekcijsko brizgo odstranite iz podstavka.
• 3 ml (recommended) graduated syringe
• brizga z oznakami prostornine velikosti 3 ml (priporočena).
The recommended dose of Firazyr based on body weight in children and adolescents (aged 2 to 17 years) is provided in table 1 below.
Priporočeni odmerek zdravila Firazyr na podlagi telesne mase pri otrocih in mladostnikih (starih od 2
Other Endpoints Time to Onset of Primary Symptom Relief (hrs)
Čas do pojava lajšanja primarnega simptoma (ure)
FAST-3 was a randomized, placebo-controlled, parallel-group study of 98 adult patients with a median age of 36 years.
98 odraslih bolnikih z mediano starostjo 36 let.
Change in Composite Investigator-Assessed Symptom Score at 2 hours
Sprememba sestavljenega rezultata simptomov, ki jih je ocenjeval raziskovalec, po
Number of subjects in ITT Population 36
Število oseb v populaciji, ki so jih nameravali zdraviti
Hypodermic needle is included in the pack.
Igla za subkutano aplikacijo je priložena pakiranju.
2a) Preparing the syringe for children and adolescents (2-17 years) weighing 65 kg or less 2b) Preparing the syringe and needle for injection (all patients) 3) Preparing the injection site
2b) Priprava brizge in igle za injiciranje (za vse bolnike) 3) Priprava mesta injiciranja 4) Injiciranje raztopine
26 kg to 40 kg
Od 26 kg do 40 kg
12 kg to 25 kg
Od 12 kg do 25 kg
One pre-filled syringe and one 25G needle.
Ena igla 25G
Firazyr is available as a single pack containing one pre-filled syringe with one needle or as a multipack containing three pre-filled syringes with three needles.
Firazyr je na voljo v posamičnem pakiranju, ki vsebuje eno napolnjeno injekcijsko brizgo in eno iglo,
Children and adolescents aged 2-17 years
2a) Priprava brizge za otroke in mladostnike (stare 2-17 let)
Median time to onset of symptom relief (hours)
Mediana časa do nastopa olajšanja simptomov (v urah)
Additional injection site reactions (pressure sensation, bruising, reduced sensation and/or numbness, raised itchy skin rash and warmth).
Zelo pogosti (lahko se pojavijo pri več kot 1 od 10 bolnikov): dodatne reakcije na mestu injiciranja (občutek pritiska, podplutbe, zmanjšan čut in/ali otopelost, izbočen srbeč kožni izpuščaj ter občutek toplote)
Step-by-Step Instructions for Injection 1) General Information
Navodila za injiciranje po korakih
Baseline VAS(mm)
koprivnica (urtikarija)
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu, kjer lahko najdete tudi povezave do drugih spletnih strani o redkih boleznih in zdravljenju.
51.0 All episodes (N = 56)
51,0 Vse epizode
• Screw the syringe on the needle still fixed in the needle cap.
• Napolnjeno injekcijsko brizgo privijte na iglo, ki je še vedno zaščitena s pokrovčkom.
Other medicines and Firazyr
3 injekcije zdravila Firazyr.
41 kg to 50 kg
Od 41 kg do 50 kg
Each 3 ml pre-filled syringe contains icatibant acetate equivalent to 30 mg icatibant.
Ena 3 ml napolnjena injekcijska brizga vsebuje 30 mg ikatibanta v obliki ikatibant acetata.
Subcutaneous use Read the package leaflet before use For single use only
Pred uporabo preberite priloženo navodilo.
Transferring the icatibant solution to the graduated syringe:
Prenos raztopine ikatibanta v brizgo z oznakami prostornine:
Fatigue, lethargy, tiredness, somnolence, and dizziness have been reported following the use of Firazyr.
Firazyr so poročali o primerih utrujenosti, letargije, somnolence in omotice.
Solution for injection.
Raztopina za injiciranje
• Turn the connected syringes so that the pre-filled syringe is on top (see below image).
• Obrnite priključeni brizgi tako, da je napolnjena injekcijska brizga zgoraj.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {BLISTER TRAY LID}
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Tranexamic acid
Injiciranje raztopine
Always use this medicine exactly as your doctor has told you.
Kako uporabljati zdravilo Firazyr Pri uporabi tega zdravila natančno upoštevajte navodila svojega zdravnika.
Time to InvestigatorAssessed Initial Visual Symptom Improvement (hrs)
Čas do prvotnega vidnega izboljšanja simptomov, kot ga je ocenil raziskovalec (ure)
What you need to know before you use Firazyr 3.
Kaj je zdravilo Firazyr in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Firazyr Kako uporabljati zdravilo Firazyr
Where the dose is less than 30 mg (3 ml), the following equipment is required to extract the appropriate dose (see below): a) Firazyr pre-filled syringe (containing icatibant solution) b) Connector (adapter) c) 3 ml graduated syringe
a) napolnjena injekcijska brizga z zdravilom Firazyr (ki vsebuje raztopino ikatibanta) b) vmesnik (adapter) c) brizga z oznakami prostornine, velikosti 3 ml
Time to Subject-Assessed Initial Symptom Improvement (hrs)
Čas do prvotnega izboljšanja simptomov, kot so ga ocenili preskušanci (ure)
Biotransformation
Telesna masa
Immunogenicity
Imunogenost:
• Withdraw the required volume of icatibant solution.
• Izvlecite raztopino ikatibanta, ki ustreza potrebni prostornini za injiciranje.
Primary Endpoint Time to Onset of Symptom Relief-- Composite VAS (hrs)
Čas do pojava lajšanja simptomov - sestavljena lestvica VAS (ure)
Package Leaflet: Information for the user Firazyr 30 mg solution for injection pre-filled syringe
NAVODILO ZA UPORABO Firazyr 30 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
PHARMACEUTICAL PARTICULARS 6.1 List of excipients
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev klorid ocetna kislina, koncentrirana (za uravnavanje pH)
Firazyr is intended for use under the guidance of a healthcare professional.
Zdravstveni delavec mora bolniku ali njegovemu negovalcu dati navodila za uporabo zdravila Firazyr.
--1 Attenuated infectious bursal disease virus, strain 1052, live, 101.48 to 102.63 PU* per dose * PU: Potency Units
--1 Oslabljeni virus infekcijske bolezni burze, sev 1052, živi, od 101.48 do 102.63 PU* na odmerek * PU: Potency Units - enote za izražanje jakosti
Immediate packaging
Pakiranje za takojšnjo uporabo
Content
Karenca
MA (EU) number (Invented) name Strength Pharmaceutical Form
Številka (EU) DzP (Izmišljeno) ime
250 µg Solution for injection
250 µg raztopina za injiciranje intravenska uporaba viala (steklena)
Content (concentration)
Način uporabe Stična ovojnina Vsebina (koncentracija)
• A copy of the SPC
• Izvod SPC-ja
• Emphasis that: o Severe haemorrhagic events are more frequent in patients ≥ 75 years of age (including fatal events) or those weighing < 60 kg o Treatment with prasugrel is generally not recommended for patients of ≥ 75 years of age.
• S poudarkom na: o Hude krvavitve so pogostejše pri bolnikih starih ≥ 75 let (vključno s smrtnimi primeri) ali s telesno maso < 60 kg. o Zdravljenje s prasugrelom na splošno ni priporočeno za bolnike stare ≥ 75 let.
The MAH provides educational material to all physicians who may be involved in treating patients with prasugrel.
Imetnik dovoljenja za promet z zdravilom posreduje gradivo za izobraževanje vsem zdravnikom, ki bi lahko bili vključeni v zdravljenje bolnikov s prasugrelom.
o Patients weighing < 60 kg should have a reduced maintenance dose of 5mg o The evidence for a 5mg dose is based only on PK/PD analyses and no clinical data currently exist on the safety of this dose in the at risk sub groups.
o Če je po skrbni oceni lečečega zdravnika glede posameznikove koristi/tveganja zdravljenje v starostni skupini ≥ 75 let potrebno, mora biti po enkratnemu 60 mg polnilnemu odmerku predpisan nižji vzdrževalni odmerek 5 mg. o Bolniki s telesno maso < 60 kg morajo jemati nižji vzdrževalni odmerek 5 mg. o Podatki za 5 mg odmerek so osnovani samo na farmakodinamičnih/farmakokinetičnih analizah, saj trenutno ni na voljo kliničnih podatkov glede varnosti tega odmerka pri tveganih podskupinah bolnikov.
The format and means of dissemination, of this material should be discussed by the MAH with the appropriate learned societies.
Oblika in način razdeljevanja tega gradiva morata biti dogovorjena med imetnikom dovoljenja za promet z zdravilom in ustreznimi izobraževanimi ustanovami.
Eggs were sampled twice daily.
Jajca so vzorčili dvakrat dnevno.
Three distinct multi-resistant strains were isolated.
Izolirani so bili trije različni, večkratno odporni izolati.
No specific artificial challenge studies were available.
Na voljo ni bilo posebnih študij z umetno izpostavitvijo.
These were achieved at about 2-4 hours after dosing.
Ti vrednosti sta bili doseženi v 2-4 urah po odmerjanju.
It has been authorised in 16 EU Member States.
Dovoljenje za promet z zdravilom ima v 16 državah članicah.
If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.
Če to ni mogoče, mora zdravljenje temeljiti na lokalnih (regionalnih, na ravni kmetije) epidemioloških podatkih o dovzetnosti ciljnih bakterij.
The words “For animal treatment only” and conditions or restrictions regarding supply and use, if applicable
Besedilo “Samo za živali” in pogoji ali omejitve glede oskrbe in uporabe, če je smiselno
No resistant strains were found.
Odpornih sevov niso našli.
In these studies doses were expressed as concentrations in drinking water.
V teh študijah so bili odmerki izraženi kot koncentracija v pitni vodi.
The resistance situation for these pathogens is considered favourable.
Odpornost pri teh patogenih velja za ugodno.
The recommended harmonised indications and dosing regimens have not been extended and consequently the use of the product as recommended in the product information should not lead to increased exposure of the environment.
Priporočene usklajene indikacije in režimi odmerjanja niso bili razširjeni, zato uporaba zdravila v skladu s priporočilom v informacijah o zdravilu ne bi smela privesti do večje izpostavljenosti okolja.
When medicating large volumes of water, prepare a concentrated solution first and then dilute to the required final concentration.
Pri pripravi večjih količin vode z dodanim zdravilom najprej pripravite koncentrirano raztopino in jo nato razredčite do potrebne končne koncentracije.
This suggests that reduced sensitivity of individual Lawsonia strains can occur but as there have been no reported adverse events in the EU regarding treatment of ileitis failures it suggests that such reduced sensitivity has not developed extensively in the EU.
To kaže, da je zmanjšana občutljivost posameznih sevov rodu Lawsonia možna, a ker v EU še niso poročali o neželenih učinkih v zvezi z neuspešnim zdravljenjem ileitisa, kaže, da se v EU zmanjšana občutljivost še ni pojavila v večjem obsegu.
ATC vet code: QJ 01 XQ 01
Oznaka ATC vet: QJ01XQ01
Overall summary of the scientific evaluation of Denagard 45% and its associated names (see Annex I)
Splošni povzetek znanstvenega vrednotenja zdravila Denagard 45% in povezanih imen (glejte Prilogo I)
Germany referred the issue due to divergent national decisions having been taken by the EU Member States resulting in discrepancies in the product information for Denagard 45%.
Nemčija je zadevo napotila zaradi različnih nacionalnih odločitev, ki so jih sprejele države članice, kar je privedlo do razlik med informacijami o zdravilu za zdravilo Denegard 45%.
It does not appear to have any adverse effect on overall performance of the birds or efficacy of the veterinary medicinal product but water intake should be monitored at frequent intervals, especially in hot weather.
Ni videti, da bi to imelo neželene učinke na splošno zmogljivost ptic ali učinkovitost zdravila za uporabo v veterinarski medicini, vendar je treba vnos vode pogosto spremljati, zlasti v vročem vremenu.
Tiamulin has been shown to act at the 70S ribosome level and the primary binding sites are on the 50S subunit.
Tiamulin dokazano deluje na ravni ribosoma 70S, primarna vezavna mesta pa so na podenoti 50S.
Residues in eggs were well below the MRL at all time points.
Ostanki v jajcih so bili v vseh časovnih točkah precej pod najvišjimi mejnimi vrednostmi ostankov.
The actual doses in mg/kg body weight could only be estimated.
Dejanske odmerke v mg/kg telesne mase je bilo mogoče le oceniti.
Marketing authorisation holders
Imetnik dovoljenja za promet
The harmonised product information of Denagard 45% contains the necessary information to ensure the safe and effective use of the product.
Usklajene informacije o zdravilu Denagard 45% vsebujejo potrebne informacije za zagotavljanje varne in učinkovite uporabe zdravila.
26 Rue de la Chapelle 68330 Huningue France
Elanco France SAS 26 Rue de la Chapelle 68330 Huningue Francija
Bactericidal concentrations can be reached but vary according to the bacterium.
Baktericidne koncentracije se lahko dosežejo, vendar so odvisne od bakterije.
Remove contaminated feed as soon as possible and replace with feed not containing the tiamulinincompatible ionophores.
Odstranite kontaminirano krmo takoj, ko je mogoče, in jo zamenjajte s krmo, ki ne vsebuje s tiamulinom nezdružljivih ionoforjev.
The in vitro susceptibility data available to support the indication are limited.
Podatki o občutljivosti in vitro v podporo indikaciji so omejeni.
Users are advised to take appropriate precautions when handling the product in order to avoid exposure.
Uporabnikom se svetuje, naj med ravnanjem z zdravilom upoštevajo ustrezne previdnostne ukrepe, da se izognejo izpostavljenosti.
Due to the irritant properties, it is also recommended to wear a dust mask to minimise inhalation exposure.
Zaradi dražilnih lastnosti je priporočljiva tudi uporaba protiprašne maske, da se zmanjša inhalacijska izpostavljenost.
Risks for users were considered low and adequate information is included in the product information to ensure the safety for the user.
Tveganja za uporabnike so bila ocenjena kot nizka, informacije o zdravilu pa vsebujejo ustrezne informacije za zagotavljanje varnosti uporabnikov.
Pigs were treated at the intended dose and sacrificed 24 hours, 3, 4, 5 and 6 days after last administration.
Prašiče so zdravili s predvidenim odmerkom in jih nato 24 ur, 3, 4, 5 in 6 dni po zadnjem odmerku žrtvovali.
Excretion is mainly via the bile (55-65%) and kidney (15-30%) as mainly microbiologically inactive metabolites and is quite rapid, 99% of the dose within 48 hours.
Izločanje poteka predvsem z žolčem (55-65 %) in skozi ledvice (15-30 %), v glavnem v obliki mikrobiološko neaktivnih presnovkov, in je precej hitro, saj se 99 % odmerka izloči v 48 urah.
Animals with reduced water intake and/or in a debilitated condition should be treated parenterally.
Živali z zmanjšanim vnosom vode in/ali poslabšanim splošnim zdravstvenim stanjem je treba zdraviti parenteralno.
Recent M. meleagridis-isolates are difficult to obtain as it was eradicated from most breeding flocks and only rarely occurs in the field.
Novejše izolate M. meleagridis je težko pridobiti, saj je bila bakterija pri večini matičnih jat izkoreninjena, na terenu pa je redka.
The single mode susceptibility pattern suggested that there has been little resistance development to date.
En sam način občutljivosti kaže, da se je odpornost do zdaj le malo razvijala.
It appears to inhibit microbial protein production by producing biochemically inactive initiation complexes, which prevent elongation of the polypeptide chain.
Kaže, da zavira tvorbo mikrobnih beljakovin tako, da proizvaja biokemijsko neaktivne iniciacijske komplekse, ki preprečujejo podaljševanje polipeptidne verige.
Shelf life after dilution or reconstitution according to directions: The solution remains stable for 24 hours.
Rok uporabnosti po razredčenju ali rekonstituciji v skladu z navodili: Raztopina ostane stabilna 24 ur.
This includes the specification of target pathogens, replacement of the prevention claim by metaphylaxis and clear dose recommendations based on mg tiamulin hydrogen fumarate/kg body weight for each target species and indication as well as prudent use recommendations for antimicrobial veterinary medicinal products authorised in the EU.
To vključuje opredelitev ciljnih patogenov, zamenjavo predhodne trditve o preprečevanju z metafilakso in jasna priporočila za odmerjanje na podlagi mg tiamulinijevega hidrogenfumarata/kg telesne mase za vsako ciljno vrsto in indikacijo ter priporočila za preudarno rabo protimikrobnih zdravil za uporabo v veterinarski medicini, odobrenih v EU.
On 25 August 2015 Germany submitted a referral notification in accordance with Article 34(1) of Directive 2001/82/EC, to the CVMP/European Medicines Agency for Denagard 45% and its associated names (thereafter called Denagard 45%).
Nemčija je 25. avgusta 2015 odboru CVMP Evropski agenciji za zdravila v skladu s členom 34(1) Direktive 2001/82/ES predložila obvestilo o napotitvi za zdravilo Denegard 45% in povezana imena (v nadaljevanju zdravilo Denegard 45%).
Do not use in cases of hypersensitivity to the active substance or to the excipient.
Ne uporabite v primerih preobčutljivosti na učinkovino ali na katero koli pomožno snov.
The susceptibility patterns determined in these studies were of a wild-type pattern indicating that no resistance had developed in the period investigated.
Občutljivost,ugotovljena v teh študijah, je bila podobna kot občutljivost divjega tipa, kar kaže, da se v preučevanem obdobju odpornost ni razvila.
The epidemiological cut-off value was considered at 16 µg/ml which corresponds to the current Clinical and Laboratory Standards Institute (CLSI) standard (S ≤16 µg/ml, R ≥32 µg/ml).
Epidemiološka mejna vrednost je bila ocenjena kot 16 µg/ml, kar ustreza trenutnemu standardu Inštituta za klinične in laboratorijske standarde (CLSI) (S ≤ 16 µg/ml, R ≥ 32 µg/ml).
List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, marketing authorisation holders in the Member States
Seznam imen, farmacevtske oblike, jakosti zdravila za uporabo v veterinarski medicine, živalskih vrst, načina uporabe, imetnikov dovoljenja za promet v državah članicah
Wattanaphansak et al. (2009)5, tested 10 isolates of L. intracellularis (six from USA, four from Europe).
(2009)5 so testirali 10 izolatov L. intracellularis (šest iz ZDA, štiri iz Evrope).
The feed should be tested for the ionophores prior to use if there is any suspicion that contamination of the feed might occur.
Pred uporabo krme je treba le-to testirati na vsebnost ionoforjev, če obstaja kakršen koli sum na kontaminacijo krme.
2370 Arendonk Belgium
Hoge Mauw 900 2370 Arendonk Belgija
The in vitro susceptibility of M. gallisepticum and M. synoviae from chickens and turkeys was tested intwo studies with isolates from European Member States collected from 2005-2007, and 2010-2013, and in one study with global isolates collected before 1997.
Občutljivost in vitro M. gallisepticum in M. synoviae pri piščancih in puranih so testirali v dveh študijah z izolati iz držav članic, zbranih v obdobjih 2005-2007 in 2010-2013, in v eni študiji z globalnimi izolati, zbranimi pred letom 1997.
The risk for users is related to the potential for contamination of the user's eyes and topical exposure of skin when preparing the product for administration.
Tveganje za uporabnike je povezano z možnostjo kontaminacije uporabnikovih oči in lokalne izpostavljenosti kože med pripravo zdravila za uporabo.
Susceptibility testing of L. intracellularis is challenging since this is an obligate intracellular organism.
Testiranje občutljivosti L. intracellularis je težavno, saj gre za obligatni znotrajcelični organizem.
Lesion score reduction and reduction in microbiological re-isolation varied from 55% to 100% for prevention/metaphylaxis but were as low as 33% to 67% for treatment of M. gallisepticum.
Zmanjšanje lezij in zmanjšanje ponovne izolacije mikroorganizmov je bilo v razponu od 55 % do 100 % pri preprečevanju/metafilaksi, pri zdravljenju M. gallisepticum pa je bilo manjše, in sicer od 33 % do 67 %.